These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

587 related items for PubMed ID: 27067232

  • 1. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Li G, Wang X, Ma D.
    Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
    [Abstract] [Full Text] [Related]

  • 2. Vortioxetine for depression in adults.
    Koesters M, Ostuzzi G, Guaiana G, Breilmann J, Barbui C.
    Cochrane Database Syst Rev; 2017 Jul 05; 7(7):CD011520. PubMed ID: 28677828
    [Abstract] [Full Text] [Related]

  • 3. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.
    Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M, Trivedi MH.
    Psychopharmacology (Berl); 2015 Jun 05; 232(12):2061-70. PubMed ID: 25575488
    [Abstract] [Full Text] [Related]

  • 4. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR, Jacobsen PL, Chen Y.
    Curr Med Res Opin; 2013 Mar 05; 29(3):217-26. PubMed ID: 23252878
    [Abstract] [Full Text] [Related]

  • 5. The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials.
    Li G, Wang X, Ma D.
    Neuropsychiatr Dis Treat; 2016 Mar 05; 12():523-31. PubMed ID: 27013879
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.
    Boulenger JP, Loft H, Olsen CK.
    Int Clin Psychopharmacol; 2014 May 05; 29(3):138-49. PubMed ID: 24257717
    [Abstract] [Full Text] [Related]

  • 7. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.
    Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Serretti A.
    J Psychiatry Neurosci; 2015 May 05; 40(3):174-86. PubMed ID: 25350320
    [Abstract] [Full Text] [Related]

  • 8. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun 05; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 9. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Jacobsen PL, Harper L, Chrones L, Chan S, Mahableshwarkar AR.
    Int Clin Psychopharmacol; 2015 Sep 05; 30(5):255-64. PubMed ID: 26020712
    [Abstract] [Full Text] [Related]

  • 10. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials.
    Berhan A, Barker A.
    BMC Psychiatry; 2014 Sep 27; 14():276. PubMed ID: 25260373
    [Abstract] [Full Text] [Related]

  • 11. Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.
    Llorca PM, Lançon C, Brignone M, Rive B, Salah S, Ereshefsky L, Francois C.
    Curr Med Res Opin; 2014 Dec 27; 30(12):2589-606. PubMed ID: 25249164
    [Abstract] [Full Text] [Related]

  • 12. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis.
    Meeker AS, Herink MC, Haxby DG, Hartung DM.
    Syst Rev; 2015 Mar 01; 4():21. PubMed ID: 25874839
    [Abstract] [Full Text] [Related]

  • 13. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME.
    Int J Neuropsychopharmacol; 2013 Mar 01; 16(2):313-21. PubMed ID: 22963932
    [Abstract] [Full Text] [Related]

  • 14. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.
    Baldwin DS, Florea I, Jacobsen PL, Zhong W, Nomikos GG.
    J Affect Disord; 2016 Dec 01; 206():140-150. PubMed ID: 27474960
    [Abstract] [Full Text] [Related]

  • 15. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
    Wang G, Gislum M, Filippov G, Montgomery S.
    Curr Med Res Opin; 2015 Apr 01; 31(4):785-94. PubMed ID: 25650503
    [Abstract] [Full Text] [Related]

  • 16. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
    Christensen MC, Loft H, McIntyre RS.
    J Affect Disord; 2018 Feb 01; 227():787-794. PubMed ID: 29689693
    [Abstract] [Full Text] [Related]

  • 17. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.
    Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, Reines E.
    J Psychopharmacol; 2016 Mar 01; 30(3):242-52. PubMed ID: 26864543
    [Abstract] [Full Text] [Related]

  • 18. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
    Montgomery SA, Nielsen RZ, Poulsen LH, Häggström L.
    Hum Psychopharmacol; 2014 Sep 01; 29(5):470-82. PubMed ID: 25087600
    [Abstract] [Full Text] [Related]

  • 19. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older.
    Nomikos GG, Tomori D, Zhong W, Affinito J, Palo W.
    CNS Spectr; 2017 Aug 01; 22(4):348-362. PubMed ID: 27869048
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.
    McIntyre RS, Florea I, Tonnoir B, Loft H, Lam RW, Christensen MC.
    J Clin Psychiatry; 2017 Jan 01; 78(1):115-121. PubMed ID: 27780334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.